Form 4: Syros Pharmaceuticals Director Peter Wirth Reports Stock Option Grant and Share Transactions
SEC Form 4
Director Peter Wirth reported the acquisition of stock options and shares of Syros Pharmaceuticals on June 5, 2024.
Summary
- On June 5, 2024, Peter Wirth, a director of Syros Pharmaceuticals, reported acquiring 4,000 shares of common stock at $0.00 and disposing of 16,000 shares.
- Wirth also acquired options to purchase 6,000 shares of common stock at an exercise price of $5.30, expiring on June 4, 2034.
- The stock options vest over one year, with 50% vesting after six months and the remainder vesting monthly.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors.
Stakeholder Impact
- The transactions may be of interest to shareholders as they provide insight into the director's holdings and investment decisions.
Key Dates
| Date | Description |
|---|---|
| 06/05/2024 | Date of transaction for common stock acquisition and disposal, and stock option grant. |
| 06/04/2034 | Expiration date of the stock options. |
| Six months after 06/05/2024 | Date when 50% of the stock options become exercisable. |
| One year after 06/05/2024 | Date when the remaining stock options are fully vested. |
| 06/07/2024 | Date of signature on the Form 4 filing. |
Keywords
Syros Pharmaceuticals, Director, Stock Options, Common Stock, Form 4, Beneficial Ownership, Peter Wirth
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.